Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedrine supplements lack "significant" abuse, should not be controlled -- coalition.

This article was originally published in The Tan Sheet

Executive Summary

EPHEDRINE-CONTAINING SUPPLEMENT ABUSE REJECTED BY INDUSTRY COALITION as a reason to assign controlled substance status to the OTC drug and dietary supplement ingredient. In April 17 comments to FDA on the World Health Organization's potential rescheduling of ephedrine, the Dietary Supplement Safety and Science Coalition (DSSSC) stresses the history of use and safety of the ingredient, stating "ephedrine is not a controlled substance in the U.S. today, nor should it be internationally."

You may also be interested in...



Metabolife Begins $1.5 Mil. Preemptive Campaign Against "20/20" Angle

Metabolife International has launched a $1.5 mil. radio, print and Internet campaign to preemptively combat what the company expects to be a negative report by ABC-TV's "20/20" on the firm's ephedra-containing supplement Metabolife 356.

Metabolife Begins $1.5 Mil. Preemptive Campaign Against "20/20" Angle

Metabolife International has launched a $1.5 mil. radio, print and Internet campaign to preemptively combat what the company expects to be a negative report by ABC-TV's "20/20" on the firm's ephedra-containing supplement Metabolife 356.

Metabolife Begins $1.5 Mil. Preemptive Campaign Against "20/20" Angle

Metabolife International has launched a $1.5 mil. radio, print and Internet campaign to preemptively combat what the company expects to be a negative report by ABC-TV's "20/20" on the firm's ephedra-containing supplement Metabolife 356.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088413

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel